Clinical studies on S 6472 granule preparation (sustained-release cefaclor) in chronic respiratory tract infections
Aonuma, S.; Oizumi, K.; Watanabe, A.; Tokue, Y.; Honda, Y.; Ono, R.; Kitamura, N.; Konno, K.; Satoh, K.
Japanese Journal of Antibiotics 41(9): 1309-1312
1988
ISSN/ISBN: 0368-2781 PMID: 3241329 Document Number: 316712
S 6472 granule preparation (sustained-release cefaclor) was orally administered to 15 patients with chronic respiratory tract infections (2 acutely exacerbated cases of chronic bronchitis, 13 cases of secondary infections consisting of 1 case of bronchial asthma, 2 cases of bronchial asthma/pulmonary emphysema, and 10 cases of bronchiectasis) at a daily dose of 750 mg divided into 2 doses administered after breakfast and dinner, for a duration of 14 days. The drug was ineffective in 3 of the 10 cases of bronchiectasis but was effective in the other 12 cases, with a rate of efficacy of 80%. There were no side effects of abnormal laboratory findings due to administration of this drug.